NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis $38.04 -0.19 (-0.50%) Closing price 05/11/2026 04:00 PM EasternExtended Trading$33.40 -4.64 (-12.18%) As of 09:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harrow Stock (NASDAQ:HROW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harrow alerts:Sign Up Key Stats Today's Range$37.30▼$39.8450-Day Range$33.28▼$54.1852-Week Range$24.50▼$54.85Volume1.55 million shsAverage Volume514,590 shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice Target$69.86Consensus RatingModerate Buy Company Overview Harrow Health, Inc. (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders. Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives. Its product portfolio includes preservative-free and compounded prescription eye drop formulations, which are distributed nationwide across all 50 states. The company leverages a targeted commercial infrastructure to support independent ophthalmologists, optometrists and surgical centers, while maintaining a research pipeline aimed at novel delivery technologies and formulations. Originally operating under the name ImprimisRx, the company officially adopted the Harrow Health name in mid-2021 to reflect its broader strategic focus on eye health. Harrow Health is led by Chairman and Chief Executive Officer Robert A. Ward, whose leadership, together with an experienced management team, has driven both commercial expansion and product innovation in the ophthalmology space.AI Generated. May Contain Errors. Read More Harrow Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreHROW MarketRank™: Harrow scored higher than 66% of companies evaluated by MarketBeat, and ranked 154th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingHarrow has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialHarrow has a consensus price target of $69.86, representing about 83.6% upside from its current price of $38.04.Amount of Analyst CoverageHarrow has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Harrow's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth414.58% Earnings GrowthEarnings for Harrow are expected to grow by 414.58% in the coming year, from $0.48 to $2.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -223.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -223.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 26.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.93% of the float of Harrow has been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 11.76, which indicates bearish sentiment.Change versus previous monthShort interest in Harrow has recently increased by 1.10%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.21 News SentimentHarrow has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Harrow this week, compared to 5 articles on an average week.Search Interest11 people have searched for HROW on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.MarketBeat Follows2 people have added Harrow to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have not sold or bought any company stock.Percentage Held by Insiders12.80% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HROW Stock News HeadlinesHarrow Announces First Quarter 2026 Financial ResultsMay 11 at 11:03 PM | markets.businessinsider.comIs Harrow (HROW) Pricing Reflect Its 65.5% One Year Surge And DCF OutlookMay 10 at 2:46 PM | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 12 at 1:00 AM | Banyan Hill Publishing (Ad)Harrow (HROW) Projected to Post Earnings on MondayMay 9 at 3:12 AM | americanbankingnews.comHarrow, Inc. (NASDAQ:HROW) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 8, 2026 | americanbankingnews.comIs Harrow, Inc. (HROW) A Good Stock To Buy Now?April 30, 2026 | finance.yahoo.comIs Harrow, Inc. (HROW) A Good Stock To Buy Now?April 30, 2026 | insidermonkey.comHarrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026April 27, 2026 | globenewswire.comSee More Headlines HROW Stock Analysis - Frequently Asked Questions How have HROW shares performed this year? Harrow's stock was trading at $49.00 at the start of the year. Since then, HROW stock has decreased by 22.4% and is now trading at $38.04. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) announced its quarterly earnings results on Monday, May, 11th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.31. The firm earned $44.20 million during the quarter, compared to the consensus estimate of $52.43 million. Harrow had a negative net margin of 1.89% and a positive trailing twelve-month return on equity of 36.51%. Who are Harrow's major shareholders? Top institutional shareholders of Harrow include Dimensional Fund Advisors LP (1.55%), Blackhawk Capital Partners LLC (0.46%), Bank of New York Mellon Corp (0.21%) and Principal Financial Group Inc. (0.14%). Insiders that own company stock include Opaleye Management Inc, Mark L Baum and Martin A Makary. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Visa (V), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/11/2026Today5/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 5 days ago, HROW's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees180Year Founded2012Price Target and Rating Average Price Target for Harrow$69.86 High Price Target$91.00 Low Price Target$63.00 Potential Upside/Downside+83.6%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.17) Trailing P/E RatioN/A Forward P/E Ratio79.25 P/E GrowthN/ANet Income-$5.14 million Net Margins-1.89% Pretax Margin-0.50% Return on Equity36.51% Return on Assets5.06% Debt Debt-to-Equity Ratio4.67 Current Ratio2.20 Quick Ratio2.06 Sales & Book Value Annual Sales$272.30 million Price / Sales5.21 Cash Flow$0.86 per share Price / Cash Flow44.23 Book Value$1.41 per share Price / Book26.98Miscellaneous Outstanding Shares37,270,000Free Float32,502,000Market Cap$1.42 billion OptionableOptionable Beta0.34 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:HROW) was last updated on 5/12/2026 by MarketBeat.com Staff. From Our PartnersRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredSpaceX Goes Public. Here's What Happens To Your IRA.When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...Americas Gold Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
